A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
Phase 1
232
about 5.5 years
18+
10 sites in CA, IL, MO +3
What this study is about
Researchers are testing a treatment called ABBV-324 to see if it causes side effects and changes the activity of cancer. The trial will involve adult participants with either hepatocellular cancer (HCC) or squamous-cell non-small cell lung cancer (LUSC). Participants will receive ABBV-324 alone or in combination with lenvatinib, and doctors will monitor them for side effects and disease progression.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take ABBV-324
- 2.Take Lenvatinib
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
lenvatinib
oral (Oral Capsule)
Primary: Number of Participants with Adverse Events (AE)s, Objective Response Rate (ORR)
Secondary: Area Under the Serum Concentration Versus Time Curve (AUC) of ABBV-324, Maximum Observed Serum Concentration (Cmax) of ABBV-324, Terminal Elimination Half-Life (t1/2) of ABBV-324, Time to Maximum Observed Serum Concentration (Tmax) of ABBV-324
Oncology